title: Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119.
abstract: AstraZeneca progressed the long acting beta(2) agonist into Phase II studies for the treatment of asthma and chronic obstructive pulmonary disease in August 2008. These three applications claim specific salt forms of three different long acting beta(2) agonists, all benzothiazolone derivatives. It would seem that one claims AZD-3199 whereas the other two claim backup compounds.
authors: Norman Consulting, Burnham, Buckinghamshire, SL1 8JW, UK. peter.norman2@btinternet.com
authors: Peter
authors: P
authors: Norman
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D052160:Benzothiazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D010330:Patents as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
chemical_list: C544523:AZD-3199; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D052160:Benzothiazoles; D001993:Bronchodilator Agents